Helix BioMedix Inc. (OTCMKTS:HXBM – Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 204 shares, an increase of 240.0% from the August 15th total of 60 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 280 shares, the days-to-cover ratio is currently 0.7 days.
Helix BioMedix Stock Up 69.0%
Shares of HXBM stock traded up $2.45 on Friday, hitting $6.00. 400 shares of the stock were exchanged, compared to its average volume of 302. The firm’s 50 day moving average is $2.30 and its two-hundred day moving average is $1.80. Helix BioMedix has a one year low of $1.00 and a one year high of $6.50.
About Helix BioMedix
Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.
Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.
See Also
- Five stocks we like better than Helix BioMedix
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Helix BioMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioMedix and related companies with MarketBeat.com's FREE daily email newsletter.
